Theravance Biopharma (TBPH) Asset Utilization Ratio (2014 - 2026)
Theravance Biopharma (TBPH) posted quarterly Asset Utilization Ratio of 0.23 for Q1 2026, up 22.52% year-over-year from 0.19 in Q1 2025, and down 3.91% quarter-over-quarter from 0.24 in Q4 2025.
Theravance Biopharma (TBPH) Asset Utilization Ratio (2014 - 2026) Analysis & Trends
Theravance Biopharma (TBPH) has reported Asset Utilization Ratio for 13 consecutive years, with 0.23 the latest figure, recorded in Q1 2026.
- In Q1 2026, Asset Utilization Ratio rose 22.52% year-over-year to 0.23; the TTM figure through Mar 2026 stood at 0.23 (up 22.52% YoY), while the FY2025 annual figure was 0.02, down 89.79% from the prior year.
- Asset Utilization Ratio eased to 0.23 in Q1 2026 per TBPH's latest filing, from 0.24 in the prior quarter.
- Across five years, Asset Utilization Ratio topped out at 0.24 in Q4 2025 and bottomed at 0.07 in Q4 2022.
- Historically, Asset Utilization Ratio has averaged 0.16 across 5 years, with a median of 0.16 in 2024.
- Annual changes were most pronounced in 2022 — Asset Utilization Ratio slumped 47.32% — and 2023, when it surged 92.71%.
- Theravance Biopharma's Asset Utilization Ratio stood at 0.07 in 2022, then soared by 92.71% to 0.14 in 2023, then advanced by 25.58% to 0.18 in 2024, then soared by 31.58% to 0.24 in 2025, then dropped by 3.91% to 0.23 in 2026.
- Business Quant data shows TBPH's Asset Utilization Ratio at 0.23 in Q1 2026, 0.24 in Q4 2025, and 0.19 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 0.47 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 0.38 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 0.69 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 186.67 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.13 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 0.90 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 0.54 |
| 10 | Theravance Biopharma | 880.59 Mn | 492.93 Mn | - | 0.22 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 0.22 |
| Mar 31, 2026 | 0.23 |
| Dec 31, 2025 | 0.24 |
| Sep 30, 2025 | 0.19 |
| Jun 30, 2025 | 0.20 |
| Mar 31, 2025 | 0.19 |
| Dec 31, 2024 | 0.18 |
| Sep 30, 2024 | 0.18 |
| Jun 30, 2024 | 0.17 |
| Mar 31, 2024 | 0.16 |
| Dec 31, 2023 | 0.14 |
| Sep 30, 2023 | 0.13 |
| Jun 30, 2023 | 0.10 |
| Mar 31, 2023 | 0.08 |
| Dec 31, 2022 | 0.07 |
| Sep 30, 2022 | 0.09 |
| Jun 30, 2022 | 0.15 |
| Mar 31, 2022 | 0.15 |
| Dec 31, 2021 | 0.14 |
| Sep 30, 2021 | 0.14 |